October 8, 2008

Warnex Becomes Exclusive Canadian Distributor for GENDIA Diagnostic Tests

Warnex Inc. (TSX: WNX) announced today that it has become the exclusive Canadian distributor of molecular diagnostic tests for GENDIA (www.gendia.net), an international network consisting of more than 50 laboratories located in the USA, Europe and Australia, offering more than 2,000 different genetic tests.

"We are pleased to collaborate with GENDIA to provide access to a vast portfolio of highly specialized genetic tests to the Canadian healthcare sector," said Mark Busgang, President and CEO of Warnex. "Warnex will assist healthcare professionals in detecting rare genetic disorders by offering tests that are not readily available in Canada. By collaborating with this network, we are making these uncommon tests more affordable while providing faster results."

GENDIA's mission is to improve the accessibility, cost-effectiveness and quality of genetic diagnostics on a global scale. Since most laboratories offer a limited number of molecular tests, the majority of genetic disorders cannot be diagnosed locally or even nationally. This network provides the opportunity to access specific tests available worldwide.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex's analytical services division provides pharmaceutical and biotechnology companies with a variety of quality control services, including traditional chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex's bioanalytical services division specializes in bioequivalence and bioavailability studies for clinical trials. Warnex's medical laboratories division focuses on genetic and biochemical testing for the healthcare industry and has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.


Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, government regulations, laboratory facilities, suppliers, employees, key customers and business partners, foreign currency risk, credit risk, liquidity risk, volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

 Contacts: Warnex Inc. Mark J. Busgang President & CEO 450-663-6724 x 310 [email protected]  Warnex Inc. Catherine Sartoros Communications Specialist 450-663-6724 x 277 [email protected]

SOURCE: Warnex Inc.